ArticleJournal of neurology2025
Added value of optic nerve lesions for multiple sclerosis diagnostic criteria.
Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Expert Panel Consensus Guidelines of the German Society of Neuroradiology on the Use of Magnetic Resonance Imaging in the Diagnosis and Monitoring of Multiple Sclerosis.Clinical neuroradiology · 2026Guideline
- Applying the 2024-revised McDonald criteria for multiple sclerosis using conventional diagnostic tools: a single-centre prospective cohort study in Germany.EClinicalMedicine · 2026Article
- Subclinical Optic Nerve Involvement in Radiologically Isolated Syndrome: Multimodal Detection and Diagnostic Impact.Annals of clinical and translational neurology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOptic neuritis is a frequent initial presentation of multiple sclerosis (MS). It has been suggested that optic nerve lesions on magnetic resonance imaging (MRI) should be considered as an additional lesion location for the demonstration of dissemination in space (DIS) in diagnostic criteria for MS. However, the potential value of optic nerve lesion(s) in MS diagnostic criteria has not yet been sufficiently investigated.
methodsWe prospectively included 79 patients presenting with the first clinical event suggestive of MS. All patients underwent neurological work-up, visual-evoked potential (VEP) testing, cerebrospinal fluid (CSF) analysis and contrast-enhanced MRI of the brain, spinal cord and optic nerves (ON). Patients were classified results according to the McDonald 2017 criteria, the MAGNIMS criteria and alternative criteria considering ON imaging findings for both DIS and dissemination in time (DIT).
results69 patients (87%) fulfilled DIS according to the MAGNIMS criteria, 67 patients (85%) according to McDonald 2017 and 70 patients (89%) according to the alternative diagnostic criteria. Including contrast enhancing ON lesions as an additional criterion for DIT and disregarding CSF results led to n = 9 (11%) additional patients fulfilling DIT and receiving the diagnosis MS compared to the McDonald 2017 and MAGNIMS criteria. Considering CSF findings in addition to MRI, 68 patients received the diagnosis of MS according to McDonald 2017 compared to 66 patients according to MAGNIMS and 69 patients according to the alternative criteria. Regarding VEP findings as an objective finding of optic nerve involvement, 67 patients had DIS according to MAGNIMS criteria and 71 patients had DIS according to alternative criteria.
conclusionsDiagnostic criteria including ON lesion on MRI lead only to a slightly higher sensitivity but lower specificity regarding the diagnosis of MS.
Indexed as
Identifiers
40272570What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.